Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

9 Months Ended

Aug. 31, 2023

Variables used to determine the fair value of the options granted for the three and nine months ended August 31, 2023 and 2022, respectively, are as follows:


	Three months ended		Nine months ended
	August 31, 2023	August 31, 2022	August 31, 2023	August 31, 2022
Weighted average values:
Expected dividends	0%	0%	0%	0%
Expected volatility	—	—	55.00%	53.23%
Risk free interest rate	—	—	3.87%	2.74%
Expected life	—	—	5 years	3 years

Stock Option Activity

Stock option activity for options with only service-based vesting conditions for the nine months ended August 31, 2023, was as follows:


				Weighted		Weighted Average Remaining
				Average		Contractual		Aggregate
	Options			Exercise Price		Term (Years)		Intrinsic Value
Outstanding at November 30, 2022		329,314		$	8.36	4.68		$	37,250
Granted		113,000			4.68				148,610
Exercised		(5,000	)		3.10				8,950
Expired/forfeited		(43,636	)		7.92				—
Outstanding at August 31, 2023		393,678		$	7.42		4.59	$	220,260
Exercisable at August 31, 2023		285,735		$	7.52		4.81	$	140,450

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups outstanding and exercisable at August 31, 2023 and related price and contractual life information are as follows:


	Outstanding						Exercisable
			Weighted Average
			Remaining		Weighted				Weighted
Range of Exercise Prices	Outstanding		Contractual Life (Years)		Average Exercise Price		Outstanding		Average Exercise Price
$3.01 to $4.00		25,000		2.44	$	3.13		25,000	$	3.13
$4.01 to $5.00		113,000		4.35	$	4.68		50,000	$	4.62
$6.01 to $7.00		14,433		7.43	$	6.50		13,549	$	6.50
$7.01 to $8.00		151,145		5.56	$	7.54		139,893	$	7.50
$9.01 to $10.00		29,000		4.51	$	9.37		14,866	$	9.37
$12.01 to $13.00		16,653		6.98	$	12.54		12,799	$	12.58
$13.01 to $14.00		44,447		1.31	$	13.50		29,628	$	13.50
		393,678		4.59	$	7.42		285,735	$	7.52

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of August 31, 2023, and changes during the nine months ended August 31, 2023, is presented below:


				Weighted Average
				Grant-Date
	Options			Fair Value
Non-vested at November 30, 2022		95,486		$	4.42
Granted		113,000			2.19
Vested		(100,543	)		3.33
Forfeited		—			—
Non-vested at August 31, 2023		107,943		$	3.10